Lannett’s Insulin Aspart Biosimilar Takes ‘Major Step’ Forward

Lannett’s Insulin Aspart On Track For Key Development Milestones After Positive Animal Study Results

 
• By Rosalind Rei

Lannett and HEC’s insulin aspart biosimilar has performed well on an animal study in a boost to its strategic pipeline. Meanwhile, their insulin glargine faces delays.  

Laboratory worker writes on clipboard, with test-tube rack in the foreground
Lannett's Insulin Aspart Is A Major Pipeline Asset For the US Firm • Source: Shutterstock

More from Strategy

More from Business